VPB1314 - ABO blood group as an additional risk factor for venous thromboembolism

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Elena Ristovska, MD

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia

Co-Author(s)

TM

Tatjana Makarovska Bojadjieva

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia
SU

Sadula Useini

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia
EV

Emilija Velkova

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia
EP

Elena Petkovic

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia
VD

Violeta Dejanova Ilijevska

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia
JT

Jasmina Trajkova

Transfusion medicine specialist
Institute for transfusion medicine, Skopje
Skopje, Skopje, Macedonia
LI

Ljuljeta Ismaili

Transfusion medicine specialist
Institute for transfusion medicine, Tetovo
Skopje, Tetovo, Macedonia
MT

Marija Tashkovska

Transfusion medicine specialist
City General Hospital 8th September, Skopje
Skopje, Skopje, Macedonia

Background: Higher thrombotic risk associated with non-O blood group individuals is observed especially when in combination with thrombophilia.

Aims: To estimate the association of ABO blood type with venous thromboembolism (VTE).

Methods: In this retrospective case control study we enrolled 40 patients with confirmed VTE. In all of them ABO blood group was determined using serologic methods such as column agglutination technique which included forward and reverse typing. Thrombophilia testing was performed in 12 patients with unprovoked VTE event.

Results: ABO distribution among VTE patients is as follows: A in 19 (47.5%), O in 5 (12.5%), B in 10 (25.0%) and AB in 6 (15.0%) patients. The prevalence of O blood group in VTE patients was significantly lower (12.5%) in comparison to non-O blood types (87.5%). Blood group A is more prevalent and group O is less prevalent in VTE patients in comparison to our general population in which the frequency of A and O blood group is 41% and 32% respectively. In 6 VTE patients Covid 19 was confirmed few weeks prior to the thrombotic event (4-A, 1-O and 1-B blood group). In 12 patients tested for thrombophilia, 36 mutations were discovered with the following frequency: FII G20210A-5.5%, FVL G1691A-13.8%, FXIII V34L-8.3%, FGB G455A -11.1%, ITGA2 C807T-5.5%, ITG B3 T1565C-2.7%, PAI-1 4G/5G675-27.7%, MTHFR C677T-25%, from which 24 were heterozygous and 12 were homozygous (2-FVL, 2-FXIII, 1-FGB, 6-PAI-1 and 1 case with MTHFR mutation). All of the patients have more than one mutation in different combinations and their ABO distribution was similar as in the rest of the VTE patients.

Conclusion(s): According to the results, individuals with non-O blood group are more prone to VTE. ABO phenotype and especially ABO genotype may be additional diagnostic tool for assessment of the VTE risk together with thrombophilia markers.